E-ISSN: 7883-6773
P-ISSN: 3457-2861
DOI: https://iigdpublishers.com/article/98
Proficient treatments are accessible for the management of osteoporotic diseases. Anti- resorptive remedies, comprising bisphosphonates and denosumab, increment bone mineral density (BMD) and diminish the hazard of breaks by 20–70%. Bonemineralisation or bimodal-efficacy of medication invigorate bone
arrangement and increment BMD more than the antiresorptive treatments. A couple of investigations have illustrated that these medicines are preferred over anti-resorptive in avoiding breaks in patients with serious osteoporosis. Bone-enhancing or bimodal-action medicines ought to be taken after by anti-resorptive remedies to keep up the break chance diminishment. The BMD picks up realised with bone-enhancing and bimodal- combat medicines are more prominent
in medication-free patients compared to patients previously exposed to anti-resorptive medicines. Nonetheless, the anti-fracture efficacy seems to be protected. Treatment disappointment will frequently lead to a reversal of medication from orally to systemically taken antiresorptive medications or from antiresorptive to bone-forming. Osteoporosis could be an incessant condition and hence needs prolonged therapy to arrange with an individualisation approach of therapy.
Eman Abdullah & Marwan M. Merkhan
B. Abrahamsen, P. Eiken, D. (2016). Prieto-Alhambra, & R. Eastell, Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: Nationwide cohort and nested case-control study,‖ BMJ, vol. 353, , doi: 10.1136/bmj.i3365.
J. D. Adachi et al., (2001). Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo- controlled extension trial,‖ Arthritis Rheum., vol. 44, no. 1, pp. 202–211, , doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W.
S. P. H. Alexander et al., (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors,‖ Br. J. Pharmacol., vol. 176, no. S1, pp. S21–S141, doi: 10.1111/bph.14748.
E. B. Andrews et al., (2012). The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years,‖ J. Bone Miner. Res., vol. 27, no. 12, pp. 2429–2437, , doi: 10.1002/jbmr.1768.
G. J. Atkins and D. M. Findlay, Osteocyte regulation of bone mineral: A little give and take,‖ Osteoporos. Int., vol. 23, no. 8, pp. 2067–2079, 2012, doi: 10.1007/s00198-012- 1915-z.